Shares of AVITA Medical (NASDAQ:RCEL) fell 14% after the company released updated revenue guidance for 2024 and 2025.
After the market close, AVITA (NASDAQ:RCEL) said it now expects to report fourth-quarter commercial revenue of about $18.4 million, down from its previously reported range
